- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04907006
A Food-drug Interaction Study of SY-004 in Healthy Subjects
A Randomized, Open-label, Two-period, Double Crossover, Single Center Study to Evaluate the Effect of High-fat Diet on the Pharmacokinetics of SY-004 in Healthy Subjects
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Anhui
-
Wuhu, Anhui, Chine, 241000
- XIE Haitang
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- The subjects can communicate well with the researchers, understand and comply with the requirements of this study, and sign the informed consent voluntarily.
- Age on the day of signing the informed consent: healthy subjects aged 18 or above, both male and female.
- At the time of screening, male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, 19.0 kg / m2 ≤ BMI ≤ 26.0 kg / m2.
- Fasting blood glucose ≥ 3.9 mmol / L and < 6.1 mmol / L.
- From one month before the informed consent to three months after the last medication, the subjects and their partners had no plans to have a child, take effective contraceptive measures voluntarily, and donate sperm or eggs.
Exclusion Criteria:
- Within 3 months before screening, a clinical trial was completed or withdrawn, or a clinical trial was currently in progress, or other medical trials were conducted. The researchers judged that it was not suitable for the trial.
- In the past, there were serious systematic diseases or family history (including cardiovascular system, digestive system, urinary system, etc.), the researchers judged that the disease status could significantly change the absorption, distribution, metabolism and excretion of the drug used in the trial, or the risk of the subjects would be increased by taking the trial drug.
- Allergic constitution, or food allergy history, or known to be allergic to study drug / similar drug.
- Previous history of hypoglycemia.
- Previous patients with postural hypotension.
- The past five years have been positive for drug abuse, drug use history or urine drug screening results.
- Those who donate blood or lose more than 400ml of blood within 4 weeks before screening, or who have received blood or blood component infusion within 4 weeks before screening, or who plan to donate blood components within 3 months after the end of the study.
- Those who have history of syncope or blood sickness, who cannot tolerate venous puncture or have difficulty in blood collection.
- Severe infection, trauma or surgical operation within 4 weeks prior to screening, or those who are scheduled to perform surgery during the study (including, but not limited to, dental operations).
- Use any prescription, over-the-counter, herbal or health care product within 2 weeks prior to screening.
- Any drugs that inhibit or induce the metabolism of liver drugs were used within 30 days before screening.
- The average alcohol intake in the first three months of screening was more than 14 units per week (1 unit = 360ml beer, 45ml of alcohol content of 40% spirits or wine 150ml), or those who could not give up drinking alcohol during the test, or those who were positive for alcohol exhalation.
- Smoking was ≥ 5 cigarettes per day within 3 months before screening, or unwilling / unable to give up smoking during the trial.
- Special requirements for diet, and those who cannot comply with the unified diet arrangement.
- No guarantee of chocolate, any caffeine or food or drink (such as Firedragon fruit, grapefruit, grapefruit, orange juice, mango, etc.) 48 hours before and during the test.
- Pregnant or lactating women, or pregnant women with positive results.
- The results of screening were positive for HBsAg, HCV, TP and HIV.
- ALT > 1.5 times of normal value was found in screening( × ULN), or glutamic transaminase (AST) >1.5 × ULN, or serum total bilirubin (TBIL) > 1.5 × ULN。
- The results of 12 lead ECG were: QT interval (qtcb) >450ms (male) or >470ms (female).
- The results of physical examination, vital signs, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen and kidney), chest CT, ECG, laboratory examination items and related auxiliary examination results were judged by the researchers to be unsuitable for the participants.
- The researchers judged that the subjects with other factors were not suitable for participating in the test.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Group-1
The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water. The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine. After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration. |
After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule(80mg) orally with 240ml warm water.
The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
|
Expérimental: Group-2
The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water. The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine. After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration. |
After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule(80mg) orally with 240ml warm water.
The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
AUC0-t
Délai: 8 days
|
Under fasting and high-fat diet, Area under the plasma concentration versus time curve (AUC) 0-t of SY-004 in human plasma.
|
8 days
|
AUC0-∞
Délai: 8 days
|
Under fasting and high-fat diet, Area under the plasma concentration versus time curve (AUC)0 - ∞ of SY-004 in human plasma.
|
8 days
|
Cmax
Délai: 8 days
|
Under fasting and high-fat diet, Peak Plasma Concentration (Cmax) of SY-004 in human plasma.
|
8 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Tmax、t1/2z、CLz/F
Délai: 8 days
|
Under fasting and high-fat diet, Peak time(Tmax) of SY-004 in human plasma.
|
8 days
|
t1/2z
Délai: 8 days
|
Under fasting and high-fat diet, Half life (T1/2z) of SY-004 in human plasma.
|
8 days
|
CLz/F
Délai: 8 days
|
Under fasting and high-fat diet, clearance (Cl) of SY-004 in human plasma.
|
8 days
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Haitang Xie, Dr, Wannan Medical College
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- SY004004
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète de type 2
-
Bnai Zion Medical CenterInconnue
-
Jiangsu HengRui Medicine Co., Ltd.Complété
-
Asahi Kasei Pharma CorporationRecrutement
-
University of MinnesotaActif, ne recrute pasHypoglycémie | Diabète sucré de type 2États-Unis
-
University of Campania "Luigi Vanvitelli"ComplétéDiabète sucré de type 2Italie
-
University of LiverpoolAstraZeneca; Clinical Practice Research DatalinkActif, ne recrute pas
-
Regor Pharmaceuticals Inc.RésiliéDiabète sucré de type 2États-Unis
-
Charles Drew University of Medicine and ScienceNational Center for Research Resources (NCRR)Résilié
-
Population Health Research InstituteNovo Nordisk A/SComplétéDiabète sucré de type 2Canada
-
Northwell HealthPatient-Centered Outcomes Research InstituteComplétéDiabète sucré de type 2 | Diabète de type 2États-Unis
Essais cliniques sur SY-004 capsule
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.ComplétéDiabète sucré de type 2Chine
-
Yabao Pharmaceutical GroupComplétéDiabète sucré de type 2 | Hyperglycémie (diabétique)Chine
-
Yabao Pharmaceutical GroupComplétéVolontaires en bonne santé | Hyperglycémie (diabétique)Chine
-
Shouyao Holdings (Beijing) Co. LTDRecrutementCancer du poumon non à petites cellules | Tumeur solide | Cancer médullaire de la thyroïdeChine
-
Shouyao Holdings (Beijing) Co. LTDRecrutementCancer du poumon non à petites cellulesChine
-
Shouyao Holdings (Beijing) Co. LTDRecrutement
-
Shouyao Holdings (Beijing) Co. LTDRecrutementTumeur solide avancéeChine
-
Shouyao Holdings (Beijing) Co. LTDRecrutementTumeur solide avancéeChine
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Suspendu
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Complété